Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.
Edwin Roger Parra CuentesJianhua ZhangDzifa Yawa DuoseEdgar G KozlovaMary W RedmanHong ChenGaniraju C ManyamGayatri KumarJianhua ZhangXingzhi SongRossana LazcanoMario L Marques-PiubelliCaddie Laberiano FernándezFrank R Rojas AlvarezBaili ZhangLen TaingAashna JhaveriJacob GeisbergJennifer AltreuterFranziska MichorJames ProvencherJoyce YuEthan CeramiRadim MoravecKasthuri KannanRajyalakshmi LuthraGheath Al-AtrashHsin-Hui HuangHui XieManishkumar PatelKai NieJocelyn HarrisKimberly ArguetaJames R LindsayRoshni BiswasStephen Van NostrandSeunghee Kim-SchulzeJhanelle E GrayRoy S HerbstIgnacio I WistubaScott N GettingerKaren KellyLyudmila BazhenovaSacha GnjaticJiun-Kae Jack LeeJianjun ZhangCara L HaymakerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
The frequency, distribution, and clustering of immune cells relative to malignant ones can impact ICI efficacy in patients with SqNSCLC. High CNV burden may contribute to the cold immune microenvironment. Soluble inflammation/immune-related proteins in the blood have the potential to monitor therapeutic benefit from ICI treatment in patients with SqNSCLC.